---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-086629"
form_type: "8-K"
ticker: "SCLX"
cik: "0001820190"
company_name: "Scilex Holding Co"
filed_at: "2024-07-25T23:59:59+00:00"
generated_at: "2026-05-31T16:21:42.619448+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Scilex appoints Annu Navani, M.D. as Class II director and committee member

## Summary
- Appointed Annu Navani, M.D. as Class II director effective July 21, 2024; she will serve on the Commercialization and Transaction Committee.
- Dr. Navani is CEO of Comprehensive Spine and Sports Center and CMO of Boomerang Healthcare; Clinical Professor at Stanford.
- Granted initial stock option for 250,000 shares vesting monthly over 48 months under Non-Employee Director Compensation Policy.
- No family relationships or related-party transactions; standard indemnification agreement entered.
- Press release issued July 23, 2024 announcing the appointment.

## SEC filing metadata
- accession: 0000950170-24-086629
- form_type: 8-K
- ticker: SCLX
- cik: 0001820190
- company_name: Scilex Holding Co
- filed_at: 2024-07-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1820190/000095017024086629/0000950170-24-086629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1820190/000095017024086629/sclx-20240721.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-086629
- JSON: https://secwatch.observer/filing/0000950170-24-086629.json
- Plain text: https://secwatch.observer/filing/0000950170-24-086629.txt

## Key facts
- Executive change
  Annu Navani, M.D. was appointed as Class II director at Scilex Holding Co.
  - Action: appointed
  - Role: Class II director
  source text: On July 21, 2024, Scilex Holding Company (the “ Company ”) appointed Annu Navani, M.D. as a Class II director of the Company and as a member of the Commercialization and Transaction Committee of the Board of Directors of the Company (the “ Board ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1820190/000095017024086629/0000950170-24-086629-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.